Multiplex Biomarker Approach for Determining Risk of Prostate-Specific Antigen-Defined Recurrence of Prostate Cancer

Daniel R. Rhodes, Martin G. Sanda, Arie P. Otte, AM Chinnaiyan, Mark A. Rubin

JNCI Journal of the National Cancer Institute · 2003 · 271 citations · 40 references

DOIFull text

Open access

Concepts

TL;DR

Molecular signatures in cancer tissue may be useful for diagnosis and are associated with survival. The study aimed to identify combinations of candidate biomarkers that could predict prostate cancer recurrence after radical prostatectomy and thus identify patients at high risk. High‑density tissue microarrays from 259 patients (over 2000 tumor samples) were stained with antibodies to 14 biomarkers, and the immunohistochemistry results were evaluated alongside clinical parameters such as tumor stage, Gleason score, and PSA, with recurrence defined as a postsurgery PSA >0.2 ng/mL. The EZH2:ECAD status—moderate or strong EZH2 expression with at most moderate ECAD—was the biomarker combination most strongly associated with recurrence, showing significant risk ratios in training, validation, and combined cohorts and a hazard ratio of 3.19 after adjusting for clinical factors, indicating its potential to identify high‑risk patients.

Abstract

Molecular signatures in cancer tissue may be useful for diagnosis and are associated with survival. We used results from high-density tissue microarrays (TMAs) to define combinations of candidate biomarkers associated with the rate of prostate cancer progression after radical prostatectomy that could identify patients at high risk for recurrence.Fourteen candidate biomarkers for prostate cancer for which antibodies are available included hepsin, pim-1 kinase, E-cadherin (ECAD; cell adhesion molecule), alpha-methylacyl-coenzyme A racemase, and EZH2 (enhancer of zeste homolog 2, a transcriptional repressor). TMAs containing more than 2000 tumor samples from 259 patients who underwent radical prostatectomy for localized prostate cancer were studied with these antibodies. Immunohistochemistry results were evaluated in conjunction with clinical parameters associated with prostate cancer progression, including tumor stage, Gleason score, and prostate-specific antigen (PSA) level. Recurrence was defined as a postsurgery PSA level of more than 0.2 ng/mL. All statistical tests were two-sided.Moderate or strong expression of EZH2 coupled with at most moderate expression of ECAD (i.e., a positive EZH2:ECAD status) was the biomarker combination that was most strongly associated with the recurrence of prostate cancer. EZH2:ECAD status was statistically significantly associated with prostate cancer recurrence in a training set of 103 patients (relative risk [RR] = 2.52, 95% confidence interval [CI] = 1.09 to 5.81; P =.021), in a validation set of 80 patients (RR = 3.72, 95% CI = 1.27 to 10.91; P =.009), and in the combined set of 183 patients (RR = 2.96, 95% CI = 1.56 to 5.61; P<.001). EZH2:ECAD status was statistically significantly associated with disease recurrence even after adjusting for clinical parameters, such as tumor stage, Gleason score, and PSA level (hazard ratio = 3.19, 95% CI = 1.50 to 6.77; P =.003).EZH2:ECAD status was statistically significantly associated with prostate cancer recurrence after radical prostatectomy and may be useful in defining a cohort of high-risk patients.

References

40